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Introduction
Recombinant adenoviral vectors efficiently transduce a wide range of dividing and nondividing cell types, making this gene delivery system valuable as a tool for studying diseases and for potential clinical use. 1 Currently, the major barrier to in vivo use of adenoviral vectors is the immune response generated against viral proteins and/or a heterologous transgene product. [2] [3] [4] [5] In mouse models, the generation of cytotoxic T lymphocytes (CTL) results in rapid elimination of transgene expressing cells, typically within 2-3 weeks, 6, 7 and the generation of neutralizing antibodies against adenoviral capsid proteins correlates with the inability to readminister vector. 6, [8] [9] [10] [11] For both CTL response and antibody generation, helper CD4
+ T lymphocytes are central. Critical costimulatory interactions between T cells and the antigen presenting cell (APC) include CD40 to CD40 ligand (CD40L) and B7 to CD28. Mice deficient in CD40 or CD40L, or mice treated with anti-CD40L blocking antibody display poor T cell-dependent antibody responses coincident with deficiencies in germinal center formation, isotype switching and memory B cell induction. 12 Interaction between B7 on the APC and CD28 on the T cell provides a necessary costimulatory signal for T cell activation, without which anergy is believed to occur. 13 As ligation of CD40 has been shown to up-regulate B7 expression on APCs, [14] [15] [16] while CD28 costimulation upregulates CD40L expression on T cells, 17 these pathways likely function in a cross-enhancing manner for maximal T cell activation.
Several recent strategies to prolong transgene expression and/or improve redosing of recombinant adenovirus have targeted the CD40-CD40L or B7-CD28 interactions. Two studies examined the effects of administration of CTLA4Ig, a recombinant molecule that binds B7 and thus blocks interaction with CD28. They determined that with CTLA4Ig treatment, CD4
+ infiltration into muscle 18 and liver 19 was reduced and stable transgene expression was observed beyond control timepoints. However, the humoral response was either unaffected 18 or was not blunted sufficiently to allow redosing. 19 Similarly, a recent study employing the anti-CD40L blocking monoclonal antibody MR-1 at the time of adenoviral vector infusion was successful at diminishing cellular immune responses for prolonged tissue expression of transgene, but redosing to liver was inefficient. 20 A more recent study determined that the combination of CTLA4-Ig and MR-1 reduced antibody response enough to allow efficient redosing with recombinant adenovirus, and transgene expression from the redosed vector persisted. 21 An alternative means of blocking T cell activation is to target the APC. When administered systemically, liposomes incorporating the drug dichloromethylene diphosphonate (clodronate) are phagocytosed by and subsequently kill hepatic Kupffer cells and splenic macrophages. 22 Such depletion of macrophages has been reported to reduce T cell-dependent humoral responses to particulate antigens. 23 Since adenovirus is a particulate antigen likely to be internalized and presented by macrophages, we hypothesized that injection of clodronate liposomes before vector infusion may reduce the immune response.
In the present study we examined the abilities of MR-1 and clodronate liposomes, either alone or in combination, to reduce immune response to recombinant adenovirus for: (1) prolonged transgene expression after a primary adenoviral vector administration; and (2) increased efficiency of redosing to liver. We found that MR-1 or clodronate liposome treatment at the time of primary virus infusion decreased humoral and cellular immune responses to virus and substantially increased the duration of transgene expression. However, only MR-1 treatment obliterated the antibody response such that efficient and stable readministration of vector to liver was achieved.
Results

MR-1 and clodronate liposomes prolong transgene expression and inhibit immune responses to vector
To assess the effects of macrophage depletion and CD40L blockade on transgene expression after a single administration of recombinant adenovirus, mice were injected intravenously (i.v.) with AdFIX on day 0, and injected with MR-1 on days −1, 0, 1, 2, 4, 6 and 9, and/or with clodronate liposomes on day −2, or left untreated. FIX levels in plasma were measured over time. Figure 1 shows that without treatment, 37 ± 7 ng/ml FIX were detected on day 8, and declined to background levels thereafter. In contrast, with clodronate liposomes, MR-1 or both, FIX levels peaked on day 21 at 224 ± 34, 102 ± 17 and 272 ± 42 ng/ml, respectively. FIX levels had not declined to background levels by day 35 (the last day tested). Interestingly, FIX levels were significantly higher with clodronate liposome treatment than with MR-1 treatment alone, at all time-points tested, suggesting that macrophage depletion enhanced the amount of transduction.
Loss of transgene expression in untreated immunocompetent mice is generally believed to be due to a specific CD4
+ CTL response. To test the effects of treatment on virus-specific immunity, we measured plasma anti-Ad IgG on day 14 and cytokine release after re-exposure of splenic lymphocytes to adenovirus in vitro. As shown in Figure 2 , prior injection of clodronate liposome resulted in 67% inhibition of the antibody response compared with untreated mice, while there was no detectable anti-Ad IgG in mice given MR-1. Cytokine release from splenic lymphocytes after re-exposure to virus particles was also affected by MR-1 and clodronate liposomes ( Figure 3 ). Both treatments resulted in decreased IL-10 and IFN-␥ release in comparison with controls, with MR-1 + clodronate liposomes more inhibitory than either alone. IL-4 was undetectable in all cases (not shown).
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Cr release assays of CD8 + -enriched splenocyte cultures indicated no killing of AdFIX-infected targets in any of the treated groups, while the untreated group showed 16% killing at an effector to target ratio of 100:1 (data not shown).
To test if the immunosuppressive effects of macrophage depletion and CD40L blockade extended to the transgene product, we determined anti-FIX IgG titers on day 35 plasma samples. Figure 4 indicates that FIX is immunogenic in untreated immunocompetent mice, eliciting a notable IgG response. As with anti-Ad, this response is severely blunted with clodronate liposome treatment, and completely blocked with MR-1 treatment.
MR-1 but not clodronate liposomes prevents anti-Ad antibody response and permits redosing
Poor transduction after redose is another major obstacle to recombinant adenovirus utility. We postulated that treatment with clodronate liposomes or MR-1 might allow for redose, with transduction efficiency dependent on inhibition of anti-Ad antibody responses. To test this, mice were given a primary dose of recombinant adenovirus (10 8 p.f.u. Ad␤gal) on day 0 concomitant with MR-1 and/or clodronate liposome treatment. Specific groups were then given a secondary dose of recombinant adenovirus (6 x 10 9 p.f.u. AdFIX) on day 24. Anti-Ad IgG and FIX levels were monitored to assess efficiency of transduction in relation to antibody response. Figure 5 shows that transduction of AdFIX was dependent on the absence of an antibody response on the day of redose. MR-1 treatment (alone or with clodronate liposomes) completely blocked or severely inhibited the generation of anti-Ad IgG (Figure 5a ). Plasma levels on day 24 (redose day) were 6 ± 6 and 25 ± 29 ng/ml for the groups that had received MR-1 and MR-1 + clodronate liposomes, respectively, compared with 12 360 ± 931 ng/ml for the untreated group. Note that the anti-Ad IgG production in clodronate liposome-treated mice was not as markedly impeded; day 13 and day 24 levels were 27 and 40% of untreated control levels, respectively, but increased thereafter. Figure 5b shows that in mice given MR-1, FIX levels after redose approximated that of the positive control group. In contrast, FIX levels in untreated mice were near background. Plasma FIX levels in animals given clodron- ate liposomes only were not significantly elevated over untreated mice. These results suggest that even low levels of antibody are capable of neutralizing i.v. injected adenovirus, with redosing achievable only when the humoral response is essentially obliterated. Thus, treatment with CD40L antibody, but not clodronate liposomes, permitted efficient redosing.
In addition to blocking the antibody response to the first vector exposure, MR-1 treatment prevented any significant elevation in antibody levels after redosing (Figure 5a ). Eight days after the day 24 redose, anti-Ad IgG levels reached 135 357 ± 27 250 ng/ml in the untreated group and 100 433 ± 44 972 ng/ml in mice given clodronate liposomes. Anti-Ad levels were only 239 ± 151 and 51 ± 42 ng/ml in the MR-1 and MR-1 + clodronate liposome-treated groups, respectively.
MR-1 also promoted prolonged expression of the redosed transgene ( Figure 5b) ; FIX levels continued to rise until day 40 to day 45 after which there was a gradual decline. Forty per cent of peak levels remained 39 days after redose. In contrast, FIX levels in positive control mice dropped to 12% of peak level 12 days after the injection of AdFIX. Because the adenovirally delivered transgene remains episomal in transduced cells, we anticipate that loss of transgene over time due to cell turnover or as yet undefined mechanisms will necessitate repetitive dosing. For this reason we tested the ability of MR-1 treatment to allow a second redose. On day 63, when FIX levels in MR-1-treated mice were 40% of peak levels, mice were given AdFIX (8 x 10 9 p.f.u.) i.v. MR-1 was administered on days −3, −1, 0, 1, 2 and 4 in relation to this second redose. Figure 6 illustrates that, similar to day 24, transduction on day 63 was dependent on anti-Ad levels at the time of redose. The mice given MR-1 only exhibited negligible day 63 anti-Ad levels, and FIX levels rose from 58 ± 5 ng/ml on day 63 to 209 ± 53 ng/ml on day 67. In mice treated with MR-1 + clodronate liposomes anti-Ad levels were also low. Correspondingly, FIX levels increased from 75 ± 10 ng/ml to 246 ± 79 ng/ml.
In previously untreated mice, MR-1 given at the time of the day 63 AdFIX injection had a limited effect with no notable rise in FIX levels. Nevertheless, MR-1 did blunt further increases in antibody concentration (1.4-fold increase). In contrast, mice not given MR-1 on day 63 exhibited an eight-fold increase in anti-Ad IgG on day 67. Table 1 allows analysis of results for individual animals and shows that day 63 AdFIX redosing was successful in the majority of MR-1 and MR-1 + clodronate liposome-treated mice. However, plasma FIX levels in one mouse in each of these groups did not change significantly from day 63 to day 67. This is most likely due to low but measurable levels of anti-Ad IgG. Interestingly, efficient transduction did occur in one mouse in the MR-1 + clodronate liposome-treated group with antiAd IgG clearly detectable. We postulate that this is because the existing antibody may lack neutralizing activity. Indeed, anti-Ad neutralizing titers for day 63 plasma samples were Ͻ20 for mice that received MR-1 with one exception. This mouse had a neutralizing titer of 20 (lowest dilution tested) and correspondingly could not be redosed with AdFIX.
FIX levels were monitored to day 94 at which time they had declined by only 18 ± 5% in mice where redosing was successful (data not shown), indicating a sustained inhibition of immune responses.
Discussion
This study investigated the effects of macrophage depletion and CD40L blockade on efficiency of transduction and duration of transgene expression after one, two and three doses of recombinant adenovirus. Both macrophage depletion and blockade of CD40-CD40L interactions were effective at enhancing and prolonging FIX expression after a primary i.v. injection of AdFIX. Previous studies with liver-directed delivery of recombinant adenovirus to immunocompetent mice indicate that a Th1-type immune response, encompassing CD4 + T cells, CD8
+ T cells and IFN-␥ production, is crucial to immune clearance of transgene. 7, 24 As CD40-CD40L interactions are involved in elicitation of IL-12 for promotion of a Th1-type response, 25 it is likely that the basis of prolonged transgene expression is the ability of MR-1 to inhibit cellular immune response to the vector. Decreased cytokine production and a lack of specific CTL activity from splenic lymphocytes after re-exposure to virus in vitro supports this concept. Our results are consistent with those of Yang and colleagues 20 where MR-1 treatment decreased immune response and stabilized transgene expression after adenovirus vector administration.
The novel finding that clodronate liposome treatment resulted in substantial prolongation of transgene expression could also be explained by a reduction in vector-specific cellular immunity. Intravenous injection of clodronate liposomes eliminates Kupffer cells from the liver and the majority of macrophages from the spleen. 
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Figure 5 MR-1 but not clodronate liposome treatment prevents anti-Ad
Kupffer cells and splenic macrophages that have picked up virus particles conceivably act as antigen presenting cells for T cell activation and generation of T celldependent humoral and cytotoxic CD8
+ T cell responses. Since activated macrophages elicit cytokines such as IL-12 and TNF-␣ that are influential in the induction of a CD4 + Th1-type response, 26 their elimination should down-regulate T cell immunity in general and Th1-type responses in particular. This possibility is supported by our results, namely, the reduction in a T cell-dependent antibody response, the lack of cytolytic activity and decreased cytokine release in splenic lymphocytes cultures.
Interestingly, clodronate liposome treatment not only prolonged expression, but also markedly enhanced FIX levels from the first time-point tested. Kupffer cells are an important component of the innate immune response involved in early (days 2-7) inflammatory response and hepatocyte death observed in liver after recombinant adenovirus injection. 2 Thus, their removal may have prevented early hepatocyte loss, and increased the effective dose of virus retained in the liver. Our results are consistent with a recent study indicating that clodronate liposome-mediated elimination of Kupffer cells before recombinant adenovirus infusion reduced innate immunity to enhance hepatic transgene product seven-to 13-fold. 27 While a specific cytolytic immune response is generally implicated in the destruction of transduced cells and resultant loss of transgene product, we cannot rule out the possibility that antibodies generated against FIX resulted in sequestration and/or clearance of FIX in untreated control groups. Indeed, our results show that anti-hFIX antibodies are generated in the absence of MR-1 or MR-1 + clodronate liposomes. Moreover, recent investigations using recombinant adenovirus expressing human ␣1-antitrypsin 5 and human FIX 28 found that loss of detectable product in the blood coincided with the appearance of antibodies, and occurred despite retention of viral DNA sequences in the liver. 5, 28 Further experimentation is necessary to reveal the relative contributions of CTL activity and antibody-mediated clearance to the loss of plasma FIX in untreated mice. Figure 5 The second part of our study addressed the effects of clodronate liposomes and MR-1 on repeated transduction of liver. We observed that treatment with MR-1 to block CD40-CD40L interactions at the time of recombinant adenoviral administration permitted efficient (near 100% of control) redosing to liver. This is in contrast to a recent report which showed that MR-1 allowed efficient redosing to lung by intratracheal delivery, but not to liver by i.v. injection (9% of control transduction). 20 However, that study used lower MR-1 doses and a shorter treatment schedule (four injections of 100 g each). Therefore, the dose of blocking antibody is likely critical. This is further supported in studies by Foy and colleagues. 29 They found that 3 x 500 g injections of MR-1 resulted in 99% reduction of T-dependent primary antibody responses, while 3 x 100 g injections reduced responses by only 66%. Taken together, this suggests that near total abrogation of the anti-adenoviral antibody response is necessary for readministration of vector i.v.
Figure 6 MR-1 treatment allows repeated redosing: anti-Ad IgG levels remain low and FIX levels increase after a second AdFIX injection (third virus injection). On day 63 mice treated as described in
In addition to allowing efficient redosing, MR-1 treatment resulted in prolonged expression of the redosed transgene. Significant levels of FIX were maintained for 6 weeks after AdFIX injection, with near 40% peak expression remaining at this time. This compares favorably with previously unimmunized control mice where expression declined rapidly. Successful redosing of adenovirus and sustained secondary transgene expression has also recently been described by Kay and colleagues 21 by co-administration of murine CTLA4Ig and MR-1, but not with either agent alone. Our success with MR-1 alone is likely due to a more complete blockade of CD40-CD40L interactions.
Although we found that clodronate liposome treatment reduced adenovirus-specific humoral responses by 60%, this was not sufficient to permit redosing. This may be because of inadequate elimination of macrophages, especially from the spleen where liposome penetration is partial, 22 and/or due to the presence of alternative antigen presenting cells (dendritic cells and B cells) .
In this study we also tested whether recombinant adenovirus could be given a third time. Importantly, the second redose proved as successful as the first, with plasma FIX levels increasing approximately three-to four-fold. Again, successful transduction corresponded to low antibody levels at the time of redose. MR-1 treatment was probably not required for transduction at this time, but it is likely to be essential for continued blockade of antibody response such that receptiveness to subsequent redosing is maintained.
The immune response against recombinant adenovirus, including that against a foreign transgene product, is presently the largest impediment to the use of adenoviral vectors in vivo. Our results show that transient immunosuppression, such as with clodronate liposomes and MR-1, may overcome this limitation.
Materials and methods
Mice Six-to 8-week-old male CBA mice (The Jackson Laboratory, Bar Harbor, ME, USA) were used for in vivo experiments presented in this study. Mice were maintained in the animal facility at the University of Iowa. All procedures were approved by the University of Iowa Animal Care and Use Committee.
Recombinant adenoviral vectors
The recombinant adenoviral vectors used in this study are derived from human adenovirus serotype 5, with deletions in the E1 region rendering them replication defective. Ad␤gal carries the Escherichia coli lacZ gene coding for ␤-galactosidase fused to the nuclear localization signal of SV40 T antigen as previously described. 30 AdFIX carries the human factor IX cDNA, and was constructed by The University of Iowa Gene Transfer Vector Core, Iowa City, IA, USA using routine methods. 31 Both vectors are driven by the Rous sarcoma virus (RSV) long terminal repeat, and contain an SV40 polyadenylation sequence downstream of the transgene coding region. These vectors were amplified and purified by The University of Iowa Gene Transfer Vector Core. 32 Clodronate liposomes and MR-1 monoclonal antibody Liposomes encapsulating dichloromethylene diphosphonate (clodronate) were generated as previously described, 22 and were used within 1 week of preparation. Clodronate was a gift from Boehringer Mannheim, Mannheim, Germany. The MR-1 hybridoma producing hamster anti-murine CD40L (gp-39) 33 was kindly provided by Dr Tom Waldschmidt at the University of Iowa, Treatment groups are as described in Figure 1 and in Materials and methods. On day 63, these mice and naive mice (positive controls for AdFIX day 63) were injected with AdFIX, and were treated (y) or not (n) with 500 g injections of MR-1 on days −3, −1, 0, 1, 2 and 4, relative to the day 63 injection. Plasma neutralization titers were determined for day 63, and plasma concentrations of anti-Ad and FIX were determined for days 63 and 67. Data are expressed for individual animals, and as group means ± s.e.m. NA, not applicable; y, yes; n, no.
Department of Pathology. Hybridoma cells were expanded in serum-free HB101 medium (The University of Iowa College of Medicine Tissue Culture/Hybridoma Facility, Iowa City, IA, USA) and antibody purified by affinity chromatography on protein G-conjugated Sepharose 4B Fast Flow (Sigma Chemical, St Louis, MO, USA).
Vector administration and treatment with MR-1 and clodronate liposomes Mice were injected i.v. into the lateral tail vein with primary or redosed recombinant adenovirus at the number of p.f.u. described in Results. On the days described in Results 500 g intraperitoneal (i.p.) injections of MR-1 were given. Clodronate liposome-treated mice were given a single i.v. injection of 200 l liposomes (containing clodronate at 5 mg/ml) on day −2 with respect to primary injection of recombinant virus. Mice that were not treated with MR-1 or clodronate liposomes received analogous injections of hamster ␥-globulin (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) or phosphate-buffered saline (PBS), respectively.
Determination of plasma anti-Ad IgG
Anti-Ad IgG concentrations were determined by Adspecific ELISA of plasma obtained from blood drawn from mice at the indicated time-points throughout the study. Briefly, recombinant adenoviral particles (10 10 particles/ml) were adsorbed on to Maxisorp microtiter plates (Sybron Corporation, Rochester, NY, USA) overnight at 4°C. All subsequent incubations were performed at room temperature. Plates were washed with PBS containing 0.01% Tween-20, and blocked with 3% bovine serum albumin in PBS for 2 h. Dilutions of plasma samples were added and plates incubated for 3 h. After washing, horseradish peroxidase-conjugated secondary antibody (goat anti-mouse IgG, Fc␥ chain-specific; Jackson ImmunoResearch) was added and plates incubated for 1 h. After washing, plates were developed with ophenylenediamine dihydrochloride (Sigma) containing 0.12% H 2 O 2 . Plates were read on a Thermomax MicroPlate Reader (Molecular Devices, Sunnyvale, CA, USA) at 490 nm, and anti-Ad IgG concentrations in plasma determined by interpolation off a standard curve generated with murine monoclonal anti-Ad antibody (Fitzgerald Industries International, Concord, MA, USA).
Determination of plasma FIX
Human FIX levels in plasma were quantified by Asserachrom IX:Ag ELISA kits purchased from American Bioproducts Company (Parsippany, NJ, USA). Assays were performed according to the manufacturer's instructions.
Splenocyte cultures and determination of cytokine concentrations Splenic leukocytes were cultured at 2.5 x 10 6 cells/ml with or without UV-inactivated AdFIX at 10 10 particles/ml in 24-well plates, in 1.5 ml of RPMI 1640 medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin, 10 mm Hepes, and 50 m ␤-mercaptoethanol. After 40 h incubation, culture medium was collected and concentrations of IFN-␥, IL-10 and IL-4 determined by cytokine capture ELISA using antibody pairs purchased from Pharmingen (San Diego, CA, USA).
Determination of plasma anti-FIX IgG ELISA was used for detection of anti-FIX IgG. Briefly, diluted human serum containing 100 ng/ml FIX was added to microtiter wells pre-coated with rabbit anti-FIX (Asserachrom IX:Ag ELISA kits; American Bioproducts), and adsorbed for 2 h at room temperature. Plates were washed and murine plasma dilutions of 1/100, 1/1000 and 1/10 000 were added in duplicate and plates incubated for 3 h. After washing, plates were incubated with goat anti-mouse IgG secondary antibody, developed, and read as described above for the anti-Ad ELISA.
Determination of anti-Ad neutralization titers
Neutralization activity in plasma samples was determined by an in vitro neutralization assay, modified from a previously described method. 8 Briefly, Ad␤gal was added to two-fold dilutions (1/20 to 1/320) of plasma samples, and the mixtures added to monolayers of HeLa cells (American Type Culture Collection, Rockville, MD, USA). After 24 h incubation, ␤-galactosidase activity in duplicate wells was assayed using a chemiluminescent Galacto-Light Plus kit (Tropix, Bedford, MA, USA), according to the manufacturer's instructions. Light emission was read for 10 s in a luminometer (Monolight 2010; Analytical Luminescence Laboratory, Ann Arbor, MI, USA). Maximal activity was determined from the mean of six control wells that had received Ad-␤gal in the absence of antiserum. Neutralization titers for plasma samples are expressed as the highest dilution exhibiting less than 50% maximal activity.
